JPMorgan says Eidos trial design removes multiple overhangs, ups to Overweight

JPMorgan analyst Anupam Rama upgraded Eidos Therapeutics to Overweight from Neutral, citing his view that the company’s design of the ATTRibute-CM study, which incorporates feedback from the FDA, removes multiple overhangs, including the need for a head-to-head study versus tafamidis and a financing overhang. The analyst, who has increased his view of the probability of success for AG10 in the ATTR-CM opportunity, also believes AG10 is likely to generate strategic interest from commercial partners. Rama raised his price target on Eidos shares to $39 from $29.
https://thefly.com/landingPageNews.php?id=2871495